Developer docs
API playgroundTry for free, no card

Search company profiles

Syntaxis

Full company profile

uuid0005ipj

Namestring
Syntaxis
Legal namestring
Sinntaxis AB
Websiteurl
sinntaxis.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Sinntaxis AB is a privately held, pre-revenue Swedish pharmaceutical company founded in 2017 as a spin-off from Lund University, co-founded with LU Holding AB. The company is developing a single platform of negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGluR5) to enhance recovery of sensory, motor, and cognitive brain functions after stroke — an indication where no approved drug therapy currently exists and where fewer than 10% of patients receive acute clot-removal treatment. Its preclinical evidence, published in the journal Brain under founder Prof. Tadeusz Wieloch, demonstrates that mGluR5 NAM treatment initiated up to 10 days post-stroke restores brain function through synaptic remodelling, with synergistic effects when combined with rehabilitation training.

The company's core asset is the mGluR5 NAM platform, and through a November 2023 option and collaboration agreement with Addex Therapeutics, Sinntaxis is co-developing dipraglurant, a phase II-ready mGlu5 NAM, as a lead drug candidate for brain injury recovery. Sinntaxis owns IP covering the use of mGluR5 NAMs for stroke recovery and operates from Lund, Sweden, within the SmiLe Incubator, with a team of 1–10 employees led by founder Tadeusz Wieloch (CEO), Chairman Christine Widstrand, and board member Lars Öhman.

Sinntaxis is pre-revenue and pre-commercial, with future revenue expected to flow from licensing royalties, co-development milestones, or eventual direct sales following regulatory approval of its drug candidates. Go-to-market will rely on licensing and co-development partnerships with larger pharmaceutical companies rather than internal sales infrastructure, given the asset-light, R&D-focused nature of the business. The addressable market is large — approximately 14 million stroke incidents globally each year and 27,000 in Sweden, with SEK 16 billion in annual societal costs in Sweden alone — but the company remains in preclinical-to-early-clinical development with a single therapeutic platform and a single lead candidate.

Short descriptiontext

Sinntaxis AB is a pre-revenue Swedish pharmaceutical company developing negative allosteric modulators of the mGluR5 receptor to enhance recovery of brain function after stroke, currently co-developing lead candidate dipraglurant with Addex Therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stroke recovery therapeutics, mGluR5 inhibitors, central nervous system drugs, neuropharmaceutical development, brain function recovery
Industry1 code
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
Product category
Central Nervous System Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeLicensing Royalties
Description

Pre-revenue pharmaceutical company developing novel therapeutics for stroke recovery. Revenue model will be through commercialization of drug candidates upon regulatory approval, likely through licensing agreements or direct pharmaceutical sales.

sinntaxis.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sinntaxis is a preclinical-to-clinical stage pharmaceutical company developing novel therapeutics based on mGluR5 negative allosteric modulators (NAMs) to enhance recovery of brain functions after stroke. Its lead drug candidate, dipraglurant (a phase II ready mGlu5 NAM), is being co-developed with Addex Therapeutics under an option and collaboration agreement. The therapy restores brain function through synaptic remodeling and can be initiated up to 10 days after stroke onset, synergistically enhancing recovery when combined with rehabilitation training.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sinntaxis is a pharmaceutical company with a single core drug discovery platform focused on mGluR5 negative allosteric modulators (NAMs) for stroke recovery. The company is developing its lead drug candidate dipraglurant (a phase II ready mGlu5 NAM) in collaboration with Addex Therapeutics. The platform employs mGluR5 inhibitors to restore brain function after stroke through synaptic remodelling.

Product and service2 records
1mGluR5 Negative Allosteric Modulators (NAMs) Platform
CategoryDrug Discovery Platform
2Dipraglurant (mGlu5 NAM)
CategoryDrug Candidate
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-30
Description

Option and collaboration agreement to jointly advance the development of dipraglurant, a phase II ready mGlu5 negative allosteric modulator, as a potential treatment for patients with brain injuries. Combines Addex's platform and know-how in allosteric modulation with Sinntaxis's neuroscience/stroke research expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Sinntaxis was founded by scientists at Lund University and LU Holding AB. Ongoing collaboration with Professor Tadeusz Wieloch's research group at the Laboratory for Experimental Brain Research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

UK-based cell therapy developer with a stroke disability program (CTX cells). Comparable as a small European clinical-stage biotech focused on post-stroke functional recovery.

TypeBroad incumbent
Description

Large global biotherapeutics franchise with established neurology, hematology, and acute-care hospital products. Comparable as a broad incumbent in stroke-adjacent therapeutic areas and a likely eventual commercial partner or acquirer.

TypeOthers
Description

Swedish biotech previously led by Tomas Eriksson (Sinntaxis's former CEO). Thematically comparable as a small Nordic clinical-stage pharmaceutical company, though its focus (pre-eclampsia, acute kidney injury) differs from Sinntaxis's stroke recovery thesis.

TypeBroad incumbent
Description

Major pharmaceutical company with large neurology and stroke research investments and established CNS commercialization infrastructure. Comparable as a broad incumbent whose scale could license or acquire late-stage stroke recovery assets.

TypeEmerging player
Description

Clinical-stage company developing 3K3A-APC, a recombinant protein being studied for acute ischemic stroke. Comparable as a focused, smaller-stroke-recovery therapeutics developer.

TypeDirect peer
Description

Biotech developing neuroprotective therapeutics for stroke and other CNS injuries. Directly comparable as a focused, clinical-stage stroke therapy company targeting post-stroke recovery and brain injury.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing DM199 (recombinant KLK1) for acute ischemic stroke. Comparable as a small, focused stroke therapy developer with a single late-stage asset.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company and Sinntaxis's co-development partner. Both companies work on mGluR5 negative allosteric modulators (dipraglurant), making Addex the most directly comparable peer by target and mechanism.

9Athersys
TypeDirect peer
Description

Clinical-stage cell therapy company whose lead program MultiStem has been investigated for ischemic stroke. Comparable as a small-cap company pursuing novel post-stroke recovery modalities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syntaxis

Central Nervous System Pharmaceuticalssinntaxis.com

Sinntaxis AB is a pre-revenue Swedish pharmaceutical company developing negative allosteric modulators of the mGluR5 receptor to enhance recovery of brain function after stroke, currently co-developing lead candidate dipraglurant with Addex Therapeutics.

What Syntaxis does

Sinntaxis AB is a privately held, pre-revenue Swedish pharmaceutical company founded in 2017 as a spin-off from Lund University, co-founded with LU Holding AB. The company is developing a single platform of negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 5 (mGluR5) to enhance recovery of sensory, motor, and cognitive brain functions after stroke — an indication where no approved drug therapy currently exists and where fewer than 10% of patients receive acute clot-removal treatment. Its preclinical evidence, published in the journal Brain under founder Prof. Tadeusz Wieloch, demonstrates that mGluR5 NAM treatment initiated up to 10 days post-stroke restores brain function through synaptic remodelling, with synergistic effects when combined with rehabilitation training.

The company's core asset is the mGluR5 NAM platform, and through a November 2023 option and collaboration agreement with Addex Therapeutics, Sinntaxis is co-developing dipraglurant, a phase II-ready mGlu5 NAM, as a lead drug candidate for brain injury recovery. Sinntaxis owns IP covering the use of mGluR5 NAMs for stroke recovery and operates from Lund, Sweden, within the SmiLe Incubator, with a team of 1–10 employees led by founder Tadeusz Wieloch (CEO), Chairman Christine Widstrand, and board member Lars Öhman.

Sinntaxis is pre-revenue and pre-commercial, with future revenue expected to flow from licensing royalties, co-development milestones, or eventual direct sales following regulatory approval of its drug candidates. Go-to-market will rely on licensing and co-development partnerships with larger pharmaceutical companies rather than internal sales infrastructure, given the asset-light, R&D-focused nature of the business. The addressable market is large — approximately 14 million stroke incidents globally each year and 27,000 in Sweden, with SEK 16 billion in annual societal costs in Sweden alone — but the company remains in preclinical-to-early-clinical development with a single therapeutic platform and a single lead candidate.

Syntaxis firmographics

Firmographics
Name
Syntaxis
Legal name
Sinntaxis AB
Website
https://sinntaxis.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Sinntaxis AB is a pre-revenue Swedish pharmaceutical company developing negative allosteric modulators of the mGluR5 receptor to enhance recovery of brain function after stroke, currently co-developing lead candidate dipraglurant with Addex Therapeutics.
Ownership category
akta.pro rank

Syntaxis industry classification

Industry
Product category
Central Nervous System Pharmaceuticals
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Stroke recovery therapeutics
  • MGluR5 inhibitors
  • Central nervous system drugs
  • Neuropharmaceutical development
  • Brain function recovery

Where Syntaxis is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Syntaxis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Drug Development: Pre-revenue pharmaceutical company developing novel therapeutics for stroke recovery. Revenue model will be through commercialization of drug candidates upon regulatory approval, likely through licensing agreements or direct pharmaceutical sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Syntaxis product offering

Product offering

Core offering

Sinntaxis is a preclinical-to-clinical stage pharmaceutical company developing novel therapeutics based on mGluR5 negative allosteric modulators (NAMs) to enhance recovery of brain functions after stroke. Its lead drug candidate, dipraglurant (a phase II ready mGlu5 NAM), is being co-developed with Addex Therapeutics under an option and collaboration agreement. The therapy restores brain function through synaptic remodeling and can be initiated up to 10 days after stroke onset, synergistically enhancing recovery when combined with rehabilitation training.

Product overview

Sinntaxis is a pharmaceutical company with a single core drug discovery platform focused on mGluR5 negative allosteric modulators (NAMs) for stroke recovery. The company is developing its lead drug candidate dipraglurant (a phase II ready mGlu5 NAM) in collaboration with Addex Therapeutics. The platform employs mGluR5 inhibitors to restore brain function after stroke through synaptic remodelling.

Differentiator

Problem solved

Functional benefit

Products and services

  • mGluR5 Negative Allosteric Modulators (NAMs) Platform
  • Dipraglurant (mGlu5 NAM)

Companies that use Syntaxis

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Syntaxis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Syntaxis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Addex TherapeuticscoreStrategic or Co-development Partner · 30 November 2023Option and collaboration agreement to jointly advance the development of dipraglurant, a phase II ready mGlu5 negative allosteric modulator, as a potential treatment for patients with brain injuries. Combines Addex's platform and know-how in allosteric modulation with Sinntaxis's neuroscience/stroke research expertise.
  • Lund UniversitycoreStrategic or Co-development Partner · 1 January 2017Sinntaxis was founded by scientists at Lund University and LU Holding AB. Ongoing collaboration with Professor Tadeusz Wieloch's research group at the Laboratory for Experimental Brain Research.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Syntaxis competitors and assessment

Company assessment

Direct peers

  • ReNeuron Group: UK-based cell therapy developer with a stroke disability program (CTX cells). Comparable as a small European clinical-stage biotech focused on post-stroke functional recovery.
  • NoNO Inc. Biotech developing neuroprotective therapeutics for stroke and other CNS injuries. Directly comparable as a focused, clinical-stage stroke therapy company targeting post-stroke recovery and brain injury.
  • DiaMedica Therapeutics: Clinical-stage biopharmaceutical company developing DM199 (recombinant KLK1) for acute ischemic stroke. Comparable as a small, focused stroke therapy developer with a single late-stage asset.
  • Addex Therapeutics: Clinical-stage biopharmaceutical company and Sinntaxis's co-development partner. Both companies work on mGluR5 negative allosteric modulators (dipraglurant), making Addex the most directly comparable peer by target and mechanism.
  • Athersys: Clinical-stage cell therapy company whose lead program MultiStem has been investigated for ischemic stroke. Comparable as a small-cap company pursuing novel post-stroke recovery modalities.

Broad incumbents

  • CSL Behring: Large global biotherapeutics franchise with established neurology, hematology, and acute-care hospital products. Comparable as a broad incumbent in stroke-adjacent therapeutic areas and a likely eventual commercial partner or acquirer.
  • Roche: Major pharmaceutical company with large neurology and stroke research investments and established CNS commercialization infrastructure. Comparable as a broad incumbent whose scale could license or acquire late-stage stroke recovery assets.

Others

  • A1M Pharma: Swedish biotech previously led by Tomas Eriksson (Sinntaxis's former CEO). Thematically comparable as a small Nordic clinical-stage pharmaceutical company, though its focus (pre-eclampsia, acute kidney injury) differs from Sinntaxis's stroke recovery thesis.

Emerging players

  • ZZ Biotech: Clinical-stage company developing 3K3A-APC, a recombinant protein being studied for acute ischemic stroke. Comparable as a focused, smaller-stroke-recovery therapeutics developer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Syntaxis social profiles

Digital presence

Syntaxis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syntaxis leadership team

Management profile

Number of profiles

Profiles3 records

Syntaxis funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syntaxis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syntaxis

What does Syntaxis do?

Sinntaxis is a preclinical-to-clinical stage pharmaceutical company developing novel therapeutics based on mGluR5 negative allosteric modulators (NAMs) to enhance recovery of brain functions after stroke. Its lead drug candidate, dipraglurant (a phase II ready mGlu5 NAM), is being co-developed with Addex Therapeutics under an option and collaboration agreement. The therapy restores brain function through synaptic remodeling and can be initiated up to 10 days after stroke onset, synergistically enhancing recovery when combined with rehabilitation training.

Is Syntaxis a public or private company?

Syntaxis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Syntaxis founded?

Syntaxis was founded in 2017. It employs 1 to 10 people.

Where is Syntaxis based?

Syntaxis is headquartered in Lund, Sweden, in the Europe region.

How does Syntaxis make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Syntaxis's main competitors?

Direct peers on record are ReNeuron Group, NoNO Inc., DiaMedica Therapeutics, Addex Therapeutics and Athersys. Broad incumbents are CSL Behring and Roche. A1M Pharma is listed as an others. ZZ Biotech is listed as an emerging player.

Does Syntaxis have an API?

No public API is recorded for Syntaxis.

What industry is Syntaxis in?

Syntaxis's product category is Central Nervous System Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals